Endometriosis is a chronic gynecological disorder characterized by pain and impaired quality of life (QoL). While pharmacological and surgical options exist, their limitations necessitate complementary strategies. The comparative effectiveness of …
Depression more common among women with gynecological disorders, study finds MSN
Endometriosis (EMS) is a prevalent, inflammatory gynecological disorder with limited effective treatments and high recurrence rates. Given the central roles of inflammation, oxidative stress, pyroptosis, and angiogenesis in its pathogenesis, …
Endometriosis is a common gynecological disorder characterized by chronic pelvic pain, infertility, and systemic symptoms, with currently limited treatment options. Amygdalin, a cyanogenic glycoside derived from bitter apricot kernels, has …
Endometriosis (EMs) is a chronic enigmatic gynecological disorder which pathogenesis have not been fully elucidated. Exosomes have been proven to participate in endometriosis. However, the role of exosomes in the …
Endometriosis is a chronic gynecological disorder marked by the growth of endometrial-like tissue outside the uterus, often resulting in pain and infertility and affecting overall quality of life. Despite its …
Gynecological diseases-encompassing polycystic ovary syndrome, endometriosis, infertility, and malignancies-represent a significant global health burden affecting women's quality of life, reproductive capacity, and long-term health outcomes. While traditional diagnostics rely on …
Ovarian endometriosis (OvE) is a gynecological disorder with endometrial tissue in the ovaries, for which effective non-invasive diagnosis and curative treatments are currently lacking. Serum samples were collected from both …
Endometriosis is a gynecological disorder marked by the formation of endometrial tissue (gland and stroma) outside the uterine cavity. Macrophages, erythrocytes, and apoptotic endometrial tissue transplant into the peritoneal cavity, …
Metabolism-regulating microspheres have evolved from conventional drug carriers into active platforms capable of spatiotemporally reprogramming pathological metabolic networks. Chronic diseases are increasingly understood to be driven by metabolic dysregulation, highlighting …